Kos Pharmaceuticals, Inc. (Nasdaq:KOSP) today announced financial results for the fourth quarter and full year ended December 31, 2005. For the fourth quarter of 2005, revenue increased 42% to a record $213.9 million, up from $150.7 million for the fourth quarter of 2004. This significant increase is in large part a result of continued strong growth of the Company's highly differentiated cholesterol products and contributions from its new hypertension portfolio following the successful transaction with Biovail, which was completed in May 2005. Revenue for the full year ended December 31, 2005, increased 51% to $751.7 million, from $497.1 million in 2004.
